687 related articles for article (PubMed ID: 30719715)
21. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
22. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
23. Anlotinib suppresses metastasis and multidrug resistance
Yan LH; Zhang D; Mo SS; Yuan H; Mo XW; Zhao JM
J Cancer; 2021; 12(7):2092-2104. PubMed ID: 33754008
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
25. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of anlotinib-induced autophagy attenuates invasion and migration by regulating epithelial-mesenchymal transition and cytoskeletal rearrangement through ATG5 in human osteosarcoma cells.
Zheng B; Sun X; Zhang L; Qu G; Ren C; Yan P; Zhou C; Yue B
Braz J Med Biol Res; 2024; 57():e13152. PubMed ID: 38381883
[TBL] [Abstract][Full Text] [Related]
27. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
28. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
30. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
32. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
[TBL] [Abstract][Full Text] [Related]
33. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
[TBL] [Abstract][Full Text] [Related]
34. New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
Sakamoto S; Inoue H; Ohba S; Kohda Y; Usami I; Masuda T; Kawada M; Nomoto A
Cancer Sci; 2015 Apr; 106(4):367-74. PubMed ID: 25640943
[TBL] [Abstract][Full Text] [Related]
35. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma.
Yasuda N; Takenaka S; Nakai S; Nakai T; Yamada S; Imura Y; Outani H; Hamada K; Yoshikawa H; Naka N
FEBS Open Bio; 2020 May; 10(5):767-779. PubMed ID: 32128992
[TBL] [Abstract][Full Text] [Related]
36. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma.
Zhang Y; Gao X; Zhu Y; Kadel D; Sun H; Chen J; Luo Q; Sun H; Yang L; Yang J; Sheng Y; Zheng Y; Zhu K; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Apr; 37(1):93. PubMed ID: 29712569
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
38. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
39. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
40. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]